While these findings suggest that TIM-3 signaling on cDC1s in breast cancer inhibits their ability to recruit CXCR3+ T cells into the TME, anti–TIM-3 treatment does not lead to an increase in intratumoral T cells [61], indicating additional effects that remain to be investigated. The gene discussed is HAVCR2; the disease is breast carcinoma.